SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* BIOTECH GROWTH N V (Last) (First) (Middle) DE RUYTERKADE 62 WILLEMSTAD (Street) CURACO P8 000000 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol VIROLOGIC INC [ VLGC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 12/29/2003
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	12/29/2003		C		2,001,074	A	$1.21(2)	2,001,074(3)	I	By Biotech Target N.V.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series C Convertible Preferred Stock	$0(4)	12/29/2003		C			242.13	(5)	(6)	Common Stock	2,001,074	(7)	0	I	By Biotech Target N.V.

1. Name and Address of Reporting Person* BIOTECH GROWTH N V (Last) (First) (Middle) DE RUYTERKADE 62 WILLEMSTAD (Street) CURACO P8 000000 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* BB BIOTECH AG (Last) (First) (Middle) VODERGASSE 3 SWITZERLAND (Street) SCHAFFHAUSEN V8 CH-8300 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

Explanation of Responses:

1. Biotech Growth N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Virologic, Inc. held directly or indirectly by Biotech Growth N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Growth N.V. The reporting person disclaims beneficial ownership of common stock except to the extent of any of its or its affiliates pecuniary interest therein.

2. The reported securities were issued upon conversion of Series C Convertible Preferred Stock held by Biotech Target N.V., a wholly-owned subsidiary of BB Biotech AG, on December 29, 2003, at a conversion price of $1.21 per share, resulting in the acquisition of 2,001,074 shares of common stock. The Series C Convertible Preferred Stock had a face value of $10,000 per share and was convertible, subject to certain limitations, into common stock at a conversion price of $1.21 per share.

3. Does not include 3,605,004 shares of common stock held directly by Biotech Growth, N.V.

4. The reported securities convert 1-for-8,264.462.

5. Immediately Exercisable.

6. N/A.

7. The reported securities were issued upon conversion of a promissory note with a principal amount equal to $2,421,304.11.

	/s/ Adrian Bruengger, Signatory Authority for Biotech Growth N.V. and BB Biotech AG	12/31/2003
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.